Skip to Main content Skip to Navigation
Journal articles

Electrochemotherapy: Progress and Prospects.

Abstract : Treatment of recurrent or unresectable cutaneous and subcutaneaous tumors continues to be a major therapeutic challenge. Electrochemotherapy (ECT) is a palliative treatment of cutaneous and subcutaneous tumor nodules for which standard treatments (e.g. radiotherapy, chemotherapy, and surgery) have failed or proved to be insufficient. ECT combines the electropulsation of tumor cells (by local application of electric pulses) and the administration of antineoplastic drugs such as cisplatin or bleomycin (either intravenous or intratumoral). The permeability of the cancer cells to these poorly permeant anti-tumor drugs is transiently increased up to a hundred-fold. ECT is thus an efficient loco-regional therapy for palliative treatment of unresectable recurrent tumor nodules with overall objective response rates of approximatively 80-90% and has satisfactory cosmetic results. The next challenge for ECT is the treatment of deep-seated tumors and metastases. The joint therapy of ECT and electrotransfer of immune-stimulating genes or electro-photodynamic therapy could be a promising strategy for cancer eradication.
Complete list of metadatas

Cited literature [38 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00680356
Contributor : Marie-Pierre Rols <>
Submitted on : Monday, March 19, 2012 - 11:57:28 AM
Last modification on : Thursday, November 5, 2020 - 3:32:28 AM
Long-term archiving on: : Wednesday, December 14, 2016 - 5:14:44 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

  • HAL Id : inserm-00680356, version 1
  • PUBMED : 22397731

Collections

Citation

Jean-Michel Escoffre, Marie-Pierre Rols. Electrochemotherapy: Progress and Prospects.. Current Pharmaceutical Design, Bentham Science Publishers, 2012, epub ahead of print. ⟨inserm-00680356⟩

Share

Metrics

Record views

225